DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Patient reports describe reduced anxiety, ADHD symptom improvement, and TBI recovery support on GLP-1s. Mechanism speculative; trials minimal.
No controlled trials. Patient narratives in NYT April 2026 coverage and Reddit threads. Possible mechanisms: dopaminergic modulation, reduced inflammation, weight-loss-driven cognitive improvement.
Mostly patient-driven. Some psychiatrists exploring off-label for refractory cases.
Standard treatments remain primary. GLP-1 use for cognitive/mental symptoms is highly speculative.
Anecdotal signals worth watching. Not a reason to start GLP-1 alone. If on for obesity, track these secondary effects.
Editorial summary. Off-label use is legal but not FDA-evaluated. Insurance typically does not cover off-label prescriptions. Not medical advice.